Single Nucleotide Variants and Somatic Aberrations of A20 in Immune-Related Diseases and Lymphoid Neoplasms
- *Corresponding Author:
- Alexander J A Deutsch
Stiftingtalstrasse 24, 8010 Graz, Austria
Tel: +43 316 385 72816
Fax: +43 316 385 73009
E-mail: [email protected]
Received date: July 14, 2016; Accepted date: September 06, 2016; Published date: September 16, 2016
Citation: Fechter K, Neumeister P, Deutsch AJA (2016) Single Nucleotide Variants and Somatic Aberrations of A20 in Immune-Related Diseases and Lymphoid Neoplasms. J Clin Cell Immunol 7: 452. doi:10.4172/2155-9899.1000452
Copyright: © 2016 Fechter K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A20- also called tumor necrosis factor (TNF) α induced protein 3 (TNFAIP3) - is an ubiquitin-modifying enzyme, which acts as negative regulator of the NF-κB pathway. Aberrant activation of NF-κB has been shown to contribute to chronic inflammation and development of cancer. Somatic mutations and epigenetic silencing at A20 have been recently identified to be involved in the development of classical Hodgkin and many other types of non- Hodgkin lymphomas, thereby rendering A20 a classical tumor suppressor. Moreover, single nucleotide polymorphisms of A20 have been described to participate in the development of autoimmune diseases of the intestinal tract, systemic lupus erythematosus, rheumatoid arthritis and diabetes mellitus Type I. Here we want to summarize different polymorphisms related to autoimmune disorders and mention other SNPs, mutations and epigenetic mechanisms affecting A20 in lymphomas and multiple myeloma.